HK1247726A1 - 烟酰胺核苷的結晶形式 - Google Patents

烟酰胺核苷的結晶形式

Info

Publication number
HK1247726A1
HK1247726A1 HK18106989.0A HK18106989A HK1247726A1 HK 1247726 A1 HK1247726 A1 HK 1247726A1 HK 18106989 A HK18106989 A HK 18106989A HK 1247726 A1 HK1247726 A1 HK 1247726A1
Authority
HK
Hong Kong
Prior art keywords
crystalline form
nicotinamide riboside
riboside
nicotinamide
crystalline
Prior art date
Application number
HK18106989.0A
Other languages
English (en)
Inventor
Erik C Carlson
Jose Osuna
Original Assignee
Grace W R & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56879695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1247726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grace W R & Co filed Critical Grace W R & Co
Publication of HK1247726A1 publication Critical patent/HK1247726A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HK18106989.0A 2015-03-09 2018-05-29 烟酰胺核苷的結晶形式 HK1247726A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562130428P 2015-03-09 2015-03-09
PCT/US2016/020537 WO2016144660A1 (en) 2015-03-09 2016-03-03 Crystalline form of nicotinamide riboside

Publications (1)

Publication Number Publication Date
HK1247726A1 true HK1247726A1 (zh) 2018-09-28

Family

ID=56879695

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106989.0A HK1247726A1 (zh) 2015-03-09 2018-05-29 烟酰胺核苷的結晶形式

Country Status (14)

Country Link
US (1) US10189872B2 (zh)
EP (1) EP3268379B1 (zh)
JP (3) JP7236215B2 (zh)
KR (1) KR102629310B1 (zh)
CN (1) CN107428791B (zh)
AU (1) AU2016229319B2 (zh)
BR (1) BR112017019409A2 (zh)
CA (1) CA2978069C (zh)
ES (1) ES2963057T3 (zh)
FI (1) FI3268379T3 (zh)
HK (1) HK1247726A1 (zh)
PL (1) PL3268379T3 (zh)
WO (1) WO2016144660A1 (zh)
ZA (1) ZA201705776B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2908332T3 (es) * 2014-07-24 2022-04-28 Grace W R & Co Forma cristalina de cloruro de ribosilnicotinamida
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
JP6949002B6 (ja) 2015-08-05 2021-11-17 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドモノヌクレオチド誘導体及びそれらの使用
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
AU2017232930B2 (en) 2016-03-16 2021-03-25 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CA3044814A1 (en) 2016-11-29 2018-06-07 Charles M. Brenner Use of nad precursors for improving maternal health and/or offspring health
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
CN111315867A (zh) 2017-06-30 2020-06-19 益力舒健康公司 合成烟酰胺核苷的方法
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN110283221A (zh) * 2018-03-19 2019-09-27 药源药物化学（上海）有限公司 杂环化合物的制备和纯化方法
WO2019219895A1 (en) * 2018-05-18 2019-11-21 Roche Diagnostics Gmbh (thio)nicotinamide ribofuranoside salts and compositions, methods of making, and uses thereof
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
MX2021006788A (es) * 2018-12-10 2022-04-01 Chromadex Inc Formas cristalinas de los ribósidos de nicotinoílo y derivados de estos, y métodos de preparación de estas.
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
KR20220039747A (ko) 2019-07-19 2022-03-29 바이오신스 아게 니코틴아미드 리보푸라노사이드 염의 제조 방법, 니코틴아미드 리보푸라노사이드 염, 및 이의 용도
CN110642897B (zh) * 2019-09-27 2021-04-06 武汉一若生物材料有限公司 一种β-烟酰胺核糖氯化物的制备方法
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
MX2023013903A (es) 2021-05-27 2023-12-11 Metro Int Biotech Llc Solidos cristalinos de mononucleotido de acido nicotinico y esteres de estos y metodos de elaboracion y uso.
CN114933621A (zh) * 2022-04-13 2022-08-23 深圳市迪克曼生物科技有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190080A (en) 1966-08-08 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US3728111A (en) 1971-09-21 1973-04-17 Asea Ab Method of manufacturing billets from powder
AU738907C (en) 1997-02-06 2002-05-16 Merck Sharp & Dohme Corp. Dinucleotides and their use
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
EP1366055A2 (en) 2000-12-15 2003-12-03 Pharmasset Limited Antiviral agents for treatment of flaviviridae infections
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
JP3748536B2 (ja) 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
ES2663226T3 (es) 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
US8399489B2 (en) 2005-02-18 2013-03-19 Astrazeneca Ab Antibacterial piperdine derivatives
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1957086B1 (en) 2005-11-18 2018-05-02 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
JP2009521408A (ja) 2005-12-02 2009-06-04 サートリス ファーマシューティカルズ， インコーポレイテッド Ｃｄｃ２様キナーゼ（ＣＬＫ）のモジュレータおよびその使用方法
WO2007136744A1 (en) 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
MX2009008022A (es) 2007-01-26 2009-12-11 Univ Washington Metodos y composiciones para tratar neuropatias.
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2010002586A2 (en) 2008-06-30 2010-01-07 Elc Management Llc Topical compositions comprising isonicotinamide
ES2400779T3 (es) 2008-08-06 2013-04-12 Sicor, Inc. Proceso para preparar un producto intermedio de azacitidina
EA019295B1 (ru) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
US20120164670A1 (en) 2009-06-23 2012-06-28 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity
AU2010275476B2 (en) 2009-07-24 2015-07-23 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US8507251B2 (en) 2009-09-28 2013-08-13 Robert J. Greenstein Medium and method for culturing Mycobacterium avium subspecies paratuberculosis
US9603862B2 (en) 2009-12-14 2017-03-28 Cornell University Activation and activators of SIRT5
US20130165398A1 (en) 2010-03-29 2013-06-27 Paul Hochegger Concentration-enhancing drink
JP5663576B2 (ja) 2010-07-06 2015-02-04 上西　秀則 神経突起伸長剤
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
WO2013002879A1 (en) 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
CA2847292A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
CN110051672A (zh) 2012-07-09 2019-07-26 诺格罗有限责任公司 使用膳食补充剂预防酒精反应
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
WO2014014828A1 (en) 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
AU2013329312A1 (en) 2012-10-09 2015-05-28 Massachusetts Institute Of Technology Treatment of age-related and mitochondrial diseases by inhibition of HIF-1 alpha function
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
JP6507158B2 (ja) 2013-10-24 2019-04-24 ザ プロクター アンド ギャンブル カンパニー 皮膚を明るくする化粧組成物
KR20150050406A (ko) 2013-10-29 2015-05-08 한림대학교 산학협력단 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
EP3063163B1 (en) 2013-10-30 2022-08-10 Chromadex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
CN105992521A (zh) 2013-11-12 2016-10-05 奥索努特拉有限责任公司 基于特咖宁的补充剂及其使用方法
WO2015099842A1 (en) 2013-12-23 2015-07-02 Abbott Laboratories Hot beverage fortifier
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
KR20160132111A (ko) 2014-03-13 2016-11-16 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Fxr 작용제와 제조방법 및 용도
US20150297508A1 (en) 2014-04-21 2015-10-22 William Andriette Topical Formulation to Enhance Genital Sensation and Function
JP2017518306A (ja) * 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
US20170202822A1 (en) 2014-07-17 2017-07-20 The Scripps Research Institute Methods and compositions for enhancing cancer therapy
ES2908332T3 (es) * 2014-07-24 2022-04-28 Grace W R & Co Forma cristalina de cloruro de ribosilnicotinamida
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida

Also Published As

Publication number Publication date
WO2016144660A1 (en) 2016-09-15
EP3268379B1 (en) 2023-11-01
FI3268379T3 (fi) 2023-12-15
JP2023030119A (ja) 2023-03-07
PL3268379T3 (pl) 2024-03-18
JP7236215B2 (ja) 2023-03-09
KR20170125893A (ko) 2017-11-15
KR102629310B1 (ko) 2024-01-24
US10189872B2 (en) 2019-01-29
CA2978069C (en) 2021-10-12
ZA201705776B (en) 2020-01-29
AU2016229319B2 (en) 2020-05-07
CN107428791A (zh) 2017-12-01
AU2016229319A1 (en) 2017-09-14
CA2978069A1 (en) 2016-09-15
EP3268379A4 (en) 2018-12-05
EP3268379A1 (en) 2018-01-17
BR112017019409A2 (pt) 2018-04-24
JP2021105030A (ja) 2021-07-26
US20180030079A1 (en) 2018-02-01
JP2018507888A (ja) 2018-03-22
CN107428791B (zh) 2024-05-28
ES2963057T3 (es) 2024-03-25

Similar Documents

Publication Publication Date Title
HK1247726A1 (zh) 烟酰胺核苷的結晶形式
PL3174891T3 (pl) Krystaliczna postać rybozydu nikotynamidu
SG11201706729SA (en) Derivatives of sobetirome
HK1252845A1 (zh) 勞拉替尼游離碱的結晶形式
EP3136857A4 (en) Crystalline form of baricitinib
IL257026A (en) Solid state forms of eluxadoline
HK1244248A1 (zh) 兩性黴素b的衍生物
HK1255112A1 (zh) 吉西他濱的晶型
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
HK1247125A1 (zh) 結晶化合物
PT3113773T (pt) Formas cristalinas do grapiprant
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL253479A0 (en) Crystalline forms of efinconazole
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
HK1255148A1 (zh) 結晶形式
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
HUP1500506A2 (en) Salts of palbociclib
IL270937A (en) Crystalline forms of saltalicib
IL261795A (en) Crystalline form